Reports Q2 revenue $57.45B, consensus $57.01B. “We delivered strong second quarter results across the enterprise, demonstrating continued momentum against our strategic priorities,” said Jason Hollar, CEO of Cardinal Health. “With strong growth in Pharmaceutical segment profit and continued progress against our Medical Improvement Plan, we are continuing to drive operational execution in our core business. Along with our recent announcements of a tech-enabled specialty acquisition and growth portfolio prioritization, we remain focused on best serving our customers and creating value for our shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CAH:
- Cardinal Health Reports Second Quarter Fiscal 2024 Results and Raises Fiscal 2024 Outlook
- M & A News: Cardinal Health (NYSE:CAH) Jumps on $1.2B Acquisition of Specialty Networks
- Cardinal Health to acquire Specialty Networks and its PPS Analytics platform, a technology enabled multi-specialty group purchasing and practice enhancement organization in urology, rheumatology and gastroenterology
- Is CAH a Buy, Before Earnings?
- Cardinal Health price target raised to $117 from $112 at JPMorgan
